TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38102544

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' medication reconciliation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Emergency physicians' medication reconciliation
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' written copy of drug history
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Medication discrepancies detected
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Categories of discrepancies
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Relationship between discrepancies and comorbidities/drugs
Number of subjects: 161
Study: 38102575

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study: 38102639

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT
Number of subjects: 0
Study: 38102647

Group type: EXPERIMENTAL
Intervention: Active tDCS (anode over F3, cathode over F4, 5 sessions/week, 30 min/day, 2 mA stimulation intensity)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS (identical protocol but with no electric stimulation)
Number of subjects: 32
Study: 38102669

Group type: EXPERIMENTAL
Intervention: Sociodemographic variables and maternal characteristics assessed in the first year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children whose mothers were older and more satisfied with the TEDDY study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Father participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children whose mothers smoked
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children whose mothers suffered from post-partum depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children whose mothers were more anxious about their child's T1D risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Father's study satisfaction
Number of subjects: 0
Study: 38102687

Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone intravenous bolus over 5 minutes
Number of subjects: 378

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 378
Study: 38103056

Group type: EXPERIMENTAL
Intervention: Angiotensin-II
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 38103088

Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 38103144

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 38103161

Group type: EXPERIMENTAL
Intervention: ReCOV 20 µg
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: ReCOV 40 µg
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 38103359

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Stress Management Training (SMT)
Number of subjects: 126
Study: 38103438

Group type: EXPERIMENTAL
Intervention: Deinstitutionalization intervention
Number of subjects: 241
Study: 38103462

Group type: EXPERIMENTAL
Intervention: Probiotic Lacticaseibacillus rhamnosus GG (LGG)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 38103646

Group type: EXPERIMENTAL
Intervention: Free amino acids
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intact protein
Number of subjects: 16
Study: 38103784

Group type: EXPERIMENTAL
Intervention: Yoga-based intervention (YBI) with personal practice videos, private sessions, daily text messages, and monetary incentives
Number of subjects: 192
Study: 38103842

Group type: EXPERIMENTAL
Intervention: Camostat 100 mg 3 times daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Camostat 200 mg 3 times daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Camostat 300 mg 3 times daily
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 38103896

Group type: EXPERIMENTAL
Intervention: Working conditions and health access
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Self-reported health status
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Exposure to zoonoses and heavy metal poisoning
Number of subjects: 539
Study: 38103913

Group type: EXPERIMENTAL
Intervention: Very early invasive strategy (IS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Standard care invasive strategy (IS)
Number of subjects: 425
Study: 38103947

Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg (DL 0) or 40 mg (DL 1) daily on days 1-28 combined with FTD/TPI 35 mg/m².
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cabozantinib and FTD/TPI combination treatment.
Number of subjects: 15
Study: 38103956

Group type: EXPERIMENTAL
Intervention: Pencil beam scanning proton therapy with a simultaneous integrated boost (SIB) approach and at least 1 rescan evaluation during the first 5 ± 2 fractions.
Number of subjects: 42
Study: 38104036

Group type: EXPERIMENTAL
Intervention: Imatinib (first-line treatment, 69.9% of patients)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Nilotinib (18.6% of patients)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Dasatinib (4.7% of patients)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: General TKI treatment adherence
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Mental health concerns
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Impact of COVID-19 on treatment
Number of subjects: 1882
Study: 38104131

Group type: EXPERIMENTAL
Intervention: Flutamide (administered orally 6-12 hours prior to prostate biopsy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo standard-of-care (with all patients receiving definitive brachytherapy)
Number of subjects: 30
Study: 38104145

Group type: EXPERIMENTAL
Intervention: Proactive opioid-sparing analgesic protocol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 33
Study: 38104476

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38104538

Group type: EXPERIMENTAL
Intervention: Non-anuric participants (cumulative 24 h UO at inclusion ≥0.05 mL kg-1 h-1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anuric participants (cumulative 24 h UO at inclusion <0.05 mL kg-1 h-1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Higher UFNET flow rates
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lower UO
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Higher UFNET
Number of subjects: 42
Study: 38104569

Group type: EXPERIMENTAL
Intervention: guselkumab 200→100 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: guselkumab 600→200 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: guselkumab 1200→200 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 309

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 309
Study: 38104575

Group type: EXPERIMENTAL
Intervention: KarXT (xanomeline-trospium)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 38104577

Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care (NSCLC subgroup)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard of care (NSCLC subgroup)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SBRT plus standard of care (breast cancer subgroup)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard of care (breast cancer subgroup)
Number of subjects: 106
Study: 38104755

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine plus azithromycin
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 1114
Study: 38104857

Group type: EXPERIMENTAL
Intervention: Intensive body weight management program with intermittent fasting (IF)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intensive body weight management program without intermittent fasting (IF)
Number of subjects: 154
Study: 38104937

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study: 38104943

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 1.5 h/night
Number of subjects: 26

Group type: COMPARATOR
Intervention: Adequate Sleep (AS) - ≥7 h sleep/night
Number of subjects: 26
Study: 38105142

Group type: EXPERIMENTAL
Intervention: Sitravatinib (120 mg QD or 100 mg QD) plus Nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Sitravatinib plus Nivolumab
Number of subjects: 244
Study: 38105176

Group type: EXPERIMENTAL
Intervention: Healthcare-assisted risk disclosure (direct letters to at-risk relatives)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (family-mediated risk disclosure)
Number of subjects: 0
Study: 38105505

Group type: EXPERIMENTAL
Intervention: Tiragolumab (2, 8, 30, 100, 400, 600, or 1200 mg) followed by atezolizumab (1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiragolumab (840 mg) followed by atezolizumab (1680 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiragolumab (840 mg) plus atezolizumab (1680 mg)
Number of subjects: 0
Study: 38105538

Group type: EXPERIMENTAL
Intervention: ERβ transfection in LAR TNBC cell lines
Number of subjects: 146

Group type: COMPARATOR
Intervention: AR
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NECTIN4 promoter interaction with AR
Number of subjects: 146
Study: 38105655

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 30
Study: 38105847

Group type: EXPERIMENTAL
Intervention: CAD/CAM V pattern plate with surgical guide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard superior-inferior miniplate fixation
Number of subjects: 26
Study: 38105911

Group type: EXPERIMENTAL
Intervention: 0.25% reproxalap ophthalmic solution
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 95
Study: 38105936

Group type: EXPERIMENTAL
Intervention: Wearable devices collecting physiological parameters
Number of subjects: 550
Study: 38105958

Group type: EXPERIMENTAL
Intervention: Nivolumab + Capecitabine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 45

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 45
Study: 38106014

Group type: EXPERIMENTAL
Intervention: Concise 3-4 minute animated video for patient education prior to TGT
Number of subjects: 150
Study: 38106133

Group type: EXPERIMENTAL
Intervention: Genotype-driven guidance of antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 38106151

Group type: EXPERIMENTAL
Intervention: Daratumumab, lenalidomide, and dexamethasone (Dara-Rd)
Number of subjects: 32
Study: 38106552

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered music
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered reading
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 432
Study: 38106555

Group type: EXPERIMENTAL
Intervention: Zapnometinib (900 mg on Day 1; 600 mg on Days 2-6)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Zapnometinib
Number of subjects: 104
Study: 38106559

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 10171

Group type: EXPERIMENTAL
Intervention: non-COVID-19 ARI
Number of subjects: 10171

Group type: COMPARATOR
Intervention: No infection
Number of subjects: 10171
Study: 38106561

Group type: EXPERIMENTAL
Intervention: Sintilimab plus nab-paclitaxel
Number of subjects: 27
Study: 38106564

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting bioadaptor
Number of subjects: 445

Group type: COMPARATOR
Intervention: Zotarolimus-eluting drug-eluting stent
Number of subjects: 445
Study: 38106570

Group type: EXPERIMENTAL
Intervention: Iptacopan (10-100 mg for days 1-21, 200 mg for days 22-84)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 27
Study: 38106893

Group type: EXPERIMENTAL
Intervention: Data to Care (D2C) model
Number of subjects: 0
Study: 38106904

Group type: EXPERIMENTAL
Intervention: mHealth app promoting physical activity (PA) and an active healthy lifestyle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth app features developed through cocreation sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative design thinking approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth app implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study: 38107263

Group type: EXPERIMENTAL
Intervention: CPX-351-containing induction 1 and 2 (Arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard daunorubicin and dexrazoxane-containing induction (Arm B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early changes in sensitive echo indices (e.g., global longitudinal strain) and cardiac biomarkers (e.g., troponin and natriuretic peptides)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert consensus-based strategies in cardiac monitoring and anthracycline dose modification
Number of subjects: 0
Study: 38107366

Group type: EXPERIMENTAL
Intervention: Short preoperative holistic risk factor screening questionnaire
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Postoperative pain assessment using NRS and DN4
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Postoperative analgesic usage
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Well-being assessment using EQ-5D-5 L
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Psychosocial pain aspects assessment using HADs and STAI-trait
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Multidimensional pain inventory (MPI, part 1)
Number of subjects: 560
Study: 38107443

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a or peginterferon beta-1a therapy (IFN)
Number of subjects: 426
Study: 38107482

Group type: EXPERIMENTAL
Intervention: Mg citrate supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 38107550

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 75
Study: 38107641

Group type: EXPERIMENTAL
Intervention: Therapeutic Chinese massage (TCM) - three weekly 25-min sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo massage sessions - three weekly 25-min sessions
Number of subjects: 20
Study: 38107648

Group type: EXPERIMENTAL
Intervention: Technology-Assisted digital biomarkers
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Established clinical assessments
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Digital health biomarkers from robotic or wearable sensing technology
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Quantitative and qualitative measures
Number of subjects: 400
Study: 38107755

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique for 4 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study: 38107760

Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 42
Study: 38107828

Group type: EXPERIMENTAL
Intervention: Ribociclib + letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palbociclib + letrozole
Number of subjects: 0
Study: 38107829

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (86.5%, 45/52)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Chemotherapy (83.3%, 40/48)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (62.5%, 25/40)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Capecitabine alone
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Negative ER expression in metastasis
Number of subjects: 314
Study: 38108112

Group type: EXPERIMENTAL
Intervention: NOSES VIIIA
Number of subjects: 352

Group type: COMPARATOR
Intervention: Small-incision assisted right hemicolectomy
Number of subjects: 352
Study: 38108208

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 38108490

Group type: EXPERIMENTAL
Intervention: Higher pain ratings (mean 3.1 on a 10-point scale for Black participants)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Pain scores at study enrollment
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Castration-resistant prostate cancer
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Pain scales
Number of subjects: 879
Study: 38108805

Group type: EXPERIMENTAL
Intervention: MenC vaccination
Number of subjects: 7186

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 7186

Group type: COMPARATOR
Intervention: PCV7 vaccination
Number of subjects: 7186

Group type: EXPERIMENTAL
Intervention: Post-PCV13 period
Number of subjects: 7186

Group type: EXPERIMENTAL
Intervention: Hib vaccination
Number of subjects: 7186

Group type: EXPERIMENTAL
Intervention: MenB ABM incidence
Number of subjects: 7186
Study: 38108909

Group type: EXPERIMENTAL
Intervention: 48-h fasting
Number of subjects: 28
Study: 38108919

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 901
Study: 38108961

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 850
Study: 38109034

Group type: EXPERIMENTAL
Intervention: Peer-mediated, theatre-based intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 47
Study: 38109117

Group type: EXPERIMENTAL
Intervention: Hypothermia (target temperature 33 °C)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Normothermia (target temperature 36.5 to 37.7 °C)
Number of subjects: 912
Study: 38109170

Group type: EXPERIMENTAL
Intervention: Web-based self-management programs including mental health education, physical activity content, and symptom management.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Technology as an aide to daily self-management.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Customization or patient centeredness in web-based self-management programs.
Number of subjects: 47
Study: 38109196

Group type: EXPERIMENTAL
Intervention: CHAMPS+EIS
Number of subjects: 100

Group type: COMPARATOR
Intervention: EIS-only
Number of subjects: 100
Study: 38109197

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 13
Study: 38109282

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0
Study: 38109364

Group type: EXPERIMENTAL
Intervention: Lactulose (nonabsorbable disaccharide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifaximin (antibiotic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal material transplantation (emerging therapeutic target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38109921

Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 1-week interval (group A)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 2-week interval (group B)
Number of subjects: 905

Group type: COMPARATOR
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 4-week interval (group C)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Comparison of group B (2-week interval) to group C (4-week interval)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Comparison of group A (1-week interval) to group C (4-week interval)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: All groups after 2 doses of nOPV2
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine
Number of subjects: 905
Study: 38109916

Group type: EXPERIMENTAL
Intervention: BI 690517 (aldosterone synthase inhibitor)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 38109984

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg QD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg QD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg QD
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Metoprolol 25 mg BID
Number of subjects: 1000
Study: 38110039

Group type: EXPERIMENTAL
Intervention: Chinese heart-healthy (CHH) diet
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 256
Study: 38110144

Group type: EXPERIMENTAL
Intervention: POCUS with tele-support
Number of subjects: 42

Group type: COMPARATOR
Intervention: POCUS without tele-support
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: POCUS (both groups)
Number of subjects: 42
Study: 38110180

Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BRJ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium Nitrate (NIT)
Number of subjects: 8
Study: 38110181

Group type: EXPERIMENTAL
Intervention: Urinary potassium concentrations in Black participants
Number of subjects: 790

Group type: COMPARATOR
Intervention: Urinary potassium in White adults
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Elevated C0-, C3-, and C5-carnitine
Number of subjects: 790
Study: 38110183

Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (school-based gardening, cooking, and nutrition trial)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Food insecurity at baseline to food secure at follow-up
Number of subjects: 619

Group type: COMPARATOR
Intervention: Remained food insecure throughout
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: 1-point increase in food insecurity
Number of subjects: 619
Study: 38110196

Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 148
Study: 38110372

Group type: EXPERIMENTAL
Intervention: P4 panel (HABP2, CD163, AFP and PIVKA-II)
Number of subjects: 1002